To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D
Voluntary participation in this study, signed informed consent, compliance is good, can cooperate with follow-up
Age 18-80 years old (including both ends), both male and female
Subjects with advanced or metastatic malignant tumors confirmed by pathological tissue or cytology, and who have failed previous standard treatments, are intolerant to standard treatments, or have no standard treatments
Have measurable lesions
Central nervous system metastasis or meningeal metastasis with clinical symptoms
Spinal cord compression that has not been treated radically by surgery and/or radiotherapy
Patients with uncontrolled tumor-related pain as judged by the investigator
A third space effusion with uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion, as determined by the investigator
Single group
SHR-2022 Injection
DrugSHR-2022 Injection is administered by intravenous (IV) infusion
Incidence of adverse events
Severity of adverse events
MTD
RP2D
Time to maximum concentration (Tmax)
Maximum concentration (Cmax)
Receptor Occupancy（OR） of SHR-2022
Anti-drug antibody (ADA) of SHR-2022
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
